Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder

Value in Health

Volumn 15, Issue 2, 2012, Pages 231-239

  Nordström, Göran ^a   Danchenko, Natalya ^b   Despiegel, Nicolas ^c   Marteau, Florence ^b  

^a Psykiatriska Kliniken   (Sweden)

^b Lundbeck   (France)

^c i3 Innovus   (France)

Author keywords

cost effectiveness; first line therapy; major depressive disorder (MDD); remission; selective norepinephrine reuptake inhibitor (SNRI); selective serotonin reuptake inhibitor (SSRI)

Indexed keywords

ESCITALOPRAM; GENERIC DRUG; LOPERAMIDE; MECLOZINE; METOCLOPRAMIDE; PARACETAMOL; PROMETHAZINE; SALIVIN; SILDENAFIL; UNCLASSIFIED DRUG; VENLAFAXINE; XERODENT; ZOPICLONE; ZOPIKLON;

ADULT; ARTICLE; CONTROLLED RELEASE FORMULATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; EJACULATION DISORDER; FATIGUE; HEADACHE; HEALTH CARE UTILIZATION; HUMAN; IMPOTENCE; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MEDICAL LEAVE; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SALIVATION; SIDE EFFECT; SOMNOLENCE; SWEATING; SWEDEN; TREATMENT DURATION; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; COST-BENEFIT ANALYSIS; CYCLOHEXANOLS; DECISION TREES; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; ECONOMICS, PHARMACEUTICAL; HUMANS; QUALITY-ADJUSTED LIFE YEARS; SWEDEN;

EID: 84858667246     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.09.011     Document Type: Article

References (27)

1. Sobocki P, Lekander I, Borgstrom F, et al. The economic burden of depression in Sweden from 1997 to 2005. Eur Psychiatry 2007;22: 146-52. (Pubitemid 46507737)
2. Thase ME, Enstuah R, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-41. (Pubitemid 32183606)
3. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and Rfluoxetine. Biol Psychiatry 2001;50:345-50. (Pubitemid 32816947)
4. Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology2004;50:57-64. (Pubitemid 38721171)
5. Bielski RJ, Ventura D, Chang C-C. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004;65:1190-6.
6. Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006;31:122-31.
7. Montgomery SA, Andersen HF. Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 2006;21:297-309. (Pubitemid 44162482)
8. Francois C, Toumi M, Aakhus AM, Hansen K. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor: comparison of cost effectiveness between escitalopram, citalpram, fluoxetine, and venlafaxine for the treatment of depression in Norway. Eur J Health Econ 2003;4:12-9. (Pubitemid 36457052)
9. Demyttenaere K, Hemels ME, Hudry J, Annemans L. A costeffectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther 2005;27:111-24. (Pubitemid 40342582)
10. Sorensen J, Stage KB, Damsbo N, et al. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care. Nord J Psychiatry 2007;61:100-8. (Pubitemid 46592480)
11. Fernandez JL, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 2005;23:155-67. (Pubitemid 40460655)
12. Kulp W, Graf von der Schulenburg J-M, Greiner W. Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany. Eur J Health Econ 2005;6:317-21. (Pubitemid 41782188)
13. Wessling A, Ramsberg J. The Dental and Pharmaceutical Benefits Agency (Tandvårds Och Läkemedelsförmånsverket, TLV). Depression: The Review of Antidepressants. Solna, Sweden; December 2008.
14. Marteau F, Despiegel N, Jonsson L. Adherence to initial antidepressant therapy is associated with lower resource use and higher health utility in a longitudinal survey of patients with depression in Sweden. Poster presented at the Congress for the International Center of Mental Health Policy and Economics (ICMPE), Venice, Italy, March 27-29, 2009.
15. Armstrong EP, Skrepnek GH, Erder MH. Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder. Curr Med Res Opin 2007;23:251-8. (Pubitemid 46333372)
16. Sullivan PW, Valuck R, Saseen J, MacFall HM. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004;18:911-32. (Pubitemid 39612019)
17. Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004;65: 44-9.
18. Gorwood P, Weiller E, Lemming O, Katona C. Escitalopram prevents relapse in older patients with major depressive disorder. Am J Geriatr Psychiatry 2007;15:581-93.
19. Mulder RT, Joyce PR, Frampton CM, et al. Six months of treatment for depression: outcome and predictors of the course of illness. Am J Psychiatry 2006;163:95-100. (Pubitemid 43050109)
20. Simon JS, Aguiar LM, Kunz NR, Lei D. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. J Psychiatr Res 2004;38:249-57. (Pubitemid 38299162)
21. Medical Expenditure Panel Survey, Agency for Healthcare Research and Quality, Center for Cost and Financing Studies. MEPS HC-052. 2000 medical conditions, June 2003. Available from: http://meps.ahrq.gov/. [Accessed January 11, 2011].
22. Cipriani A, Santilli C, Furukawa TA, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009; Issue 2: Art No. CD006532.
23. Francois C, Sintonen H, Toumi M. Introduction of escitalopram, a new SSRI in Finland: comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of the budgetary impact. J Med Econ 2002;5:91-107. (Pubitemid 37168799)
24. Hemels ME, Kasper S, Walter E, Einarson TR. Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. Curr Med Res Opin 2004;20: 869-78. (Pubitemid 38821525)
25. Wade AG, Toumi I, Hemels ME. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr Med Res Opin 2005;21:631-42.
26. Armstrong EP, Malone DC, Erder MH. A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder. Curr Med Res Opin 2008;24:1115-21. (Pubitemid 351579169)
27. ISPOR Personalized Medicine Special Interest Group (PM). Available from: http://www.ispor.org/sigs/PM.asp. [Accessed August 25, 2011].